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procedures and clinical outcomes between the two groups were analyzed using chi 
square and one-way t-tests. Costs included therapeutic management, hospitalization, 
and amputation. Outcomes included the numbers of amputations and deaths, and 
length of stay. The analysis was performed from the Singapore hospital perspective, 
using 2008 Singapore dollars. RESULTS: The LEAP group had a lower amputation 
rate (29% vs. 76%, P < 0.001), lower death rate (0.4% vs. 13.2%, P < 0.001) and 
fewer in-hospital days (17.8 days vs. 23.16 days, P = 0.048). Furthermore, implemen-
tation of the LEAP strategy generated cost savings of 2566 Singapore dollars per 
patient compared with the pre-LEAP strategy. The results were sensitive to amputation 
rates, cost per amputation, and cost per bed day. However, the LEAP is cost saving 
across all plausible variations in parameters (95% conﬁ dence interval limits for the 
reduction in amputation rates, 25% variation in costs). CONCLUSIONS: Use of 
non-randomized study data and a retrospective comparator require the results of this 
study to be interpreted with caution. However, the results suggest the LEAP strategy 
dominates standard practice for the management of patients with diabetes and CLI 
being both cost saving and more effective. 
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OBJECTIVES: The OnceMix and INITIATE studies have indicated that biphasic 
insulin aspart 30 (BIAsp 30) is more effective than insulin glargine (IGlarg) in terms 
of reductions in glycohemoglobin in type 2 diabetes patients requiring insulin initia-
tion. Our aim was to estimate the cost-effectiveness of BIAsp 30 versus IGlarg in the 
Chinese setting. METHODS: The previously published IMS Core Diabetes Model was 
used. The nephropathy, retinopathy and stroke sub-models were modiﬁ ed to incor-
porate available Chinese clinical data. Diabetes complication costs were derived from 
hospital surveys in Beijing and Chengdu. Simulated cohorts and insulin treatment 
effects were based on the OnceMix study for once-daily BIAsp 30 versus IGlarg and 
on the INITIATE study for twice-daily BIAsp 30 versus IGlarg. Life expectancy and 
direct medical costs were calculated. Projections were made over 30-year time hori-
zons, with costs and life-years discounted at 3% annually. Extensive sensitivity analy-
ses were performed, including adjustments to cardiovascular risk for Chinese ethnicity. 
RESULTS: Once-daily BIAsp 30 increased life expectancy by 0.04 years (12.37 vs. 
12.33 years) and reduced direct medical costs by Chinese Yuan (CNY) 59,710 per 
patient (CNY 229,911 vs. CNY 289,621 per patient) compared to IGlarg in the 
OnceMix-based analysis. Twice-daily BIAsp 30 increased life expectancy by 0.08 years 
(12.99 vs. 12.91 years) and reduced direct medical costs by CNY 107,349 per patient 
(CNY 303,142 vs. CNY 410,491 per patient) compared to IGlarg in the INITIATE-
based analysis. Improvements in life expectancy were driven by reduced incidences of 
most diabetes-related complications. Cost savings were attributable to lower insulin 
costs for BIAsp 30 compared to IGlarg in China. Lowering cardiovascular risk for 
Chinese ethnicity reduced the modeled clinical improvements for BIAsp 30 but 
increased treatment-related cost savings. CONCLUSIONS: BIAsp 30, either once- or 
twice-daily, improves life expectancy and is cost-saving compared to IGlarg in the 
Chinese setting. 
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OBJECTIVES: Our objective was to compare the cost-effectiveness of glimepiride 
versus pioglitazone in combination with metformin in patients with type 2 diabetes. 
METHODS: The cost-effectiveness analysis (CEA) was performed by using Markov 
Cohort Process Mode with type 2 diabetic patients. Increases in life-years gained 
(LYG) and quality-adjusted life-years (QALYs) were measured as the main indicators 
of effectiveness. Direct medical cost includes drug cost, monitoring cost (medical-
supplies expense, total medicine-preparation cost, medical treatment cost, examination 
cost), and nursing cost (charged). Direct nonmedical cost includes the money spent 
on transportation by patients and families and indirect cost includes the time cost by 
patients and families. RESULTS: The Cost-Effectiveness Analysis (CEA) results 
showed that the combination therapy of metformin and glimepiride incurs total cost 
of KRW 5,652,814 to gain 8.065 LYG and 6.524 QALY. The combination therapy 
of metformin and pioglitazone costs KRW 8,613,622 to gain respective 8.836 LYG 
and 7.159 QALY. Thus the incremental cost-effectiveness ratios (ICERs) between two 
combination therapies were estimated to be KRW 3,837,632/LYG and KRW 
4,658,636/QALY. CONCLUSIONS: In terms of ICER values, KRW 3,837,632/LYG 
and KRW 4,658,636/QALY, there is no dominant alternative therefore the cost-
effective alternative between two alternatives will be able to be selected depending on 
threshold in willingness to pay or ICER of South Korea. 
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OBJECTIVES: Because of the rising prevalence of diabetes, the objective of this study 
was to better understand the population of patients who are at high risk for developing 
diabetes, but not yet diagnosed. Speciﬁ cally, this study examined the health outcomes 
between those at-risk for developing diabetes and controls. METHODS: This study 
utilized data from two large, cross-sectional, Internet-based survey databases, supple-
mented in China with centralized locations: the 2009 US and 2009 China National 
Health and Wellness Surveys (NHWS). Applying a previously-developed algorithm 
(Bang et al, 2009), patients in each country who were not diagnosed with diabetes 
were classiﬁ ed as having or not having a high risk for developing diabetes. High-risk 
patients were compared with controls on health-related quality of life (physical com-
ponent summary (PCS) scores of the SF-12v2) and the number of emergency room 
(ER) visits, controlling for demographics (country, age, gender, ethnicity, income, 
education) and patient characteristics (BMI and Charlson comorbidity index). 
RESULTS: Of those not diagnosed with diabetes, 2.46% of patients (n = 310) in China 
and 16.64% of patients (n = 10778) in the United States were classiﬁ ed as high risk 
for diabetes. After controlling for demographics and patient characteristics, those at 
high risk for diabetes reported signiﬁ cantly lower levels of PCS (Adjusted Mean [Madj] 
= 45.5 vs. 48.8, P < 0.0001). Although high-risk patients reported signiﬁ cantly more 
ER visits than controls in China (M = 0.44 vs. 0.40) they reported signiﬁ cantly less 
than controls in the United States (M = 0.12 vs. 0.17). These effects were signiﬁ cantly 
different between countries (χ2[1] = 5.25, P = 0.022). CONCLUSIONS: Although 
substantially more US patients were at high risk for developing diabetes relative to 
Chinese patients, the health outcome differences between those at high-risk and 
controls were more dramatic in China. Chinese patients at high-risk for diabetes 
reported signiﬁ cantly worse physical quality of life and more ER visits than 
controls. 
DIABETES/ENDOCRINE DISORDERS – Patient-Reported Outcomes Studies
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OBJECTIVES: To assess the patient’s adherence to diabetic medications using 8-item 
Morisky medication adherence scale (MMAS) and to evaluate the association between 
patients’ adherence and the diabetic control outcome. METHODS: A convenience 
sample of 223 type 2 diabetic outpatients was identiﬁ ed between May and September, 
2009 from the Penang General Hospital, Penang, Malaysia. Patients who had taken 
oral antidiabetic medications with or without insulin were eligible for the research. 
Eight-item MMAS was used to assess medication adherence. Medical records were 
reviewed for Hemoglobin A1C (HbA1C) levels and other relevant clinical data. 
RESULTS: Based on the inclusion criteria, only 175 were included in the ﬁ nal analysis. 
Employing the recommended method of scoring, the mean ± SD of MMAS scores was 
6.13 ± 1.72 in which 38% were low, 44% were medium and only 17% were in high 
adherence group. Signiﬁ cant differences in educational levels, HbA1c levels, number 
of medications per day, MMAS scores among the three groups (P < 0.05). No signiﬁ -
cant differences have been found in age, sex, BMI, race, employment and diabetic 
duration among the three groups of adherence (P ≥ 0.05). MMAS scores correlates 
signiﬁ cantly with HbA1c (−0.431 P < 0.01). CONCLUSIONS: This study has shown 
that the short, easily administered 8-item MMAS is a useful tool for measuring medica-
tion adherence in diabetic patients. This study found that patients with lower score 
of MMAS had a higher HbA1c. The present study suggested that MMAS can be used 
for identifying type 2 diabetes patients with poor adherence to their medications. 
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OBJECTIVES: To assess health status, health-related quality of life (HRQoL), treat-
ment satisfaction (TS) and patient characteristics associated with these outcomes 
among Thai patients with diabetes. METHODS: Randomly selected patients with 
Type 2 diabetes aged ≥18 years were recruited from Samut Sakhon Hospital in Thai-
land from December 2008 to February 2009 in this cross-sectional study. The Thai 
versions of the EuroQol 5-Dimensions (EQ-5D) and the Audit of Diabetes-Dependent 
Quality of Life (ADDQoL-19) Questionnaire were used to assess health status and 
HRQoL, respectively, while the Diabetes Treatment Satisfaction Questionnaire status 
version (DTSQs) was used to assess satisfaction with diabetes treatment. RESULTS: 
A total of 201 patients were recruited with the majority being female, aged ≥45 years, 
of primary education and required only oral antidiabetes therapy. Their mean ± SD 
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duration of known diabetes was 6.80 ± 6.67 years. A substantial negative impact of 
diabetes on the participants’ HRQoL was observed as assessed by the ADDQoL (mean 
± SD average weighted impact (AWI) score: −3.76 ± 2.03 from the possible range −9 to 
+3), although the level of their TS was rather high as assessed by the DTSQs (mean ± 
SD TS scale total: 28.60 ± 5.53 out of 36). The participants’ EQ-5D scores (mean ± SD 
EQ-utility score: 0.74 ± 0.20; EQ-VAS score: 65.22 ± 17.54) were only slightly lower 
than the norm values for the general population (0.80 ± 0.26 and 79.74 ± 18.23 for the 
two scores, respectively). Higher income was signiﬁ cantly associated with better health 
status while lower education and unemployment status were signiﬁ cantly associated with 
poorer HRQoL. Female gender and older age were associated with higher TS. CON-
CLUSIONS: Diabetes had major impact on the participants’ HRQoL but little impact 
on health status despite a high level of TS. Patient characteristics associated with these 
outcomes were also different. 
PDB16
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OBJECTIVES: To develop a Thai version of the Audit of Diabetes-Dependent Quality 
of Life (ADDQoL-19) and to evaluate its psychometric properties among Thai patients 
with diabetes. METHODS: This study was conducted by ﬁ rstly cross-culturally adapt-
ing the original English ADDQoL-19 into Thai, followed by administering the Thai 
version together with the Thai EQ-5D and sociodemographic questionnaire to patients 
(aged >18 years) with diabetes recruited from a tertiary hospital in central Thailand 
by simple random sampling. The usefulness of a ‘not applicable’ (N/A) option and the 
necessary of weighting the impact scores, factor structure and internal consistency 
reliability of the Thai ADDQoL-19 were assessed. Data were subjected to conﬁ rma-
tory factor analysis (CFA) using structural equation modeling (SEM) and exploratory 
factor analysis (EFA) using principal component analysis (PCA). The known-groups 
validity of the Thai ADDQoL was assessed by four a priori hypotheses. RESULTS: 
The Thai ADDQoL-19 was shown to be conceptually equivalent to its original version 
and culturally relevant to Thai patients with diabetes. Its psychometric properties were 
evaluated among 201 diabetic patients (71.1% females; 81.6% primary educated; 
mean age 54.25 [SD = 9.8] years). Its unique characteristics, i.e., weighting and indi-
vidualization were proved to be necessary for a more accurate assessment of quality 
of life. The Thai ADDQoL-19 also demonstrated a good internal consistency reli-
ability, with the Cronbach’s alpha of 0.90. However, the ﬁ t indices derived from a 
CFA failed to achieve a good ﬁ t (i.e., >0.90). EFA with forced-one factor solution 
showed factor loadings above 0.40 for all items, except for sexual relationship. The 
known-groups validity was also not clear as only two hypotheses were fully fulﬁ lled. 
CONCLUSIONS: The Thai ADDQoL-19 has shown to be culturally appropriate and 
highly reliable but requires further investigations to provide more evidence on its 
factor structure and known-groups validity before its utilization in routine clinical 
settings. 
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OBJECTIVES: The two most commonly used insulin delivery devices, pens and 
syringes, have comparable safety proﬁ les and efﬁ cacy under similar use conditions. 
Therefore, the decision regarding the preferred device must be based on other consid-
erations such as treatment satisfaction, treatment adherence, health-related quality of 
life (HRQoL), health-care expenditure and utilization. METHODS: A literature search 
was conducted of published articles in peer reviewed journals listed in the US National 
Library of Medicine’s PubMed (1948–present), DIALOG including PsychInfo (1887–
present), EMCARE (nursing lit., 1995–present), BIOSIS (1993–present), EMBASE 
(Excerpta Medica, 1974–present), SciSearch (1990–present) and MEDLINE. Relevant 
manuscripts were classiﬁ ed into subcategories based on the major focus of the article 
reviewed and then subcategories were collapsed into major categories: treatment 
satisfaction, treatment adherence, HRQoL, and health-care expenditure and utiliza-
tion. RESULTS: A total of 135 publications were reviewed for inclusion of which 73 
manuscripts and nine conference abstracts/poster were deemed relevant and reviewed 
in depth. Seventeen reported ﬁ ndings from clinical trials and 13 were review articles. 
There is substantial evidence demonstrating the superior beneﬁ ts of pens over syringes. 
Treatment satisfaction and patient preference for pens over syringes was widely 
reported and patients reported that pens provided them with increased conﬁ dence in 
dose, ability to self-inject, superior convenience and overall ease of use. Pen users 
reported better treatment adherence and fewer missed insulin doses which may 
account for the reported better HbA1c control than with syringe. Health-care expen-
diture and utilization were higher in the short term for pens; however, these expendi-
tures were minor in comparison with long-term savings that result from improved 
decreases in hospitalizations, incidence of side effects, physician visits and emergency 
department visits. CONCLUSIONS: Long- and short-term diabetes management 
should beneﬁ t from the choice of pen as the insulin delivery method based on PRO 
outcomes and long term cost effectiveness. 
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OBJECTIVES: As diabetes rates rise, it is important to understand the proﬁ le of those 
who are at-risk for developing diabetes but have not yet been diagnosed. The aim of 
this study was to assess the burden for these high-risk patients. METHODS: The 
current study used US 2009, EU 2008, and Japan 2008 datasets from the National 
Health and Wellness Survey (NHWS). Implementing a previously-developed algo-
rithm, all patients not diagnosed with diabetes were classiﬁ ed as having or not having 
a high risk for developing diabetes. High-risk patients were compared with controls 
on health-related quality of life (physical component summary (PCS) scores of the 
SF-12v2) and the number of emergency room (ER) visits controlling for demographics 
(country, age, gender, ethnicity, income, education) and patient characteristics (BMI 
and Charlson comorbidity index). RESULTS: Of patients not diagnosed with diabetes, 
16.64% (n = 10778) in the United States, 14.33% (n = 7481) in the EU, and 4.05% 
(n = 750) in Japan were classiﬁ ed as being at high risk for diabetes. After controlling 
for demographics and patient characteristics, those at high risk reported signiﬁ cantly 
lower levels of PCS across all three countries (Adjusted Mean [Madj] = 46.2 vs. 49.6, 
P < 0.0001) than controls. The effect was stronger in the EU (M-adj = 45.5 vs. M-adj 
= 49.2) and weaker in Japan (M-adj = 47.9 vs. M-adj = 49.8) relative to the United 
States (M-adj = 46.6 vs. M-adj = 49.7). Those at high risk reported signiﬁ cantly fewer 
ER visits (Madj = 0.12 vs. M-adj = 0.16, P < 0.0001) than controls, however, this effect 
was reversed in Japan in that those at high risk reported signiﬁ cantly more ER visits 
than controls (M-adj = 0.21 vs. M-adj = 0.12, P < 0.0001). CONCLUSIONS: A sub-
stantial number of patients are at a high risk for developing diabetes, particularly in 
the United States and EU. The physical quality of life was signiﬁ cantly lower, particu-
larly in the EU and the United States, and in Japan this group reported signiﬁ cantly 
more ER visits than controls. 
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OBJECTIVES: Diabetes Mellitus (DM) can reduce patients’ physical well-being and 
compromise other aspects of quality of life. This study aims to investigate the health-
related quality of life (HRQoL) of DM patients under primary care, and the associa-
tions of HRQoL with demographic factors and HbA1c control. Previous studies that 
examined these associations yielded mixed results and none was done in Singapore. 
METHODS: A cross-sectional, interviewer-administered survey was conducted in 
either English or Chinese, depending on the patient’s language of preference, between 
September and December 2009 in a convenience sample of 301 DM patients who 
were ≥21 years old, on hypoglycemic agent(s), with at least a year of DM history, and 
followed up at two outpatient clinics. Survey instrument included demographic ques-
tions and one generic and one DM-speciﬁ c HRQoL measures, i.e., EQ-5D and the 
Audit of Diabetes-Dependent Quality of Life (ADDQoL), respectively. Patients’ most 
recent HbA1c values were extracted from medical records in the clinics. RESULTS: 
The average EQ-5D score was 0.89 ± 0.16 and ADDQoL average weighted impact 
(AWI) score was −2.5 ± 2.0. Pain was the most common complaint among the ﬁ ve 
EQ-5D domains (by 28% of the respondents). Lack of freedom to eat was the 
ADDQoL domain with the greatest negative impact (AWI = −3.8, on a scale of −9 to 
3). A signiﬁ cant association was observed between ADDQoL AWI and both duration 
of diabetes (P = 0.005) and use of insulin (P = 0.014). A negative correlation was 
found between HRQoL and HbA1c values in both HRQoL measures (both r = −0.2, 
P < 0.01). CONCLUSIONS: DM patients in primary care settings frequently reported 
problems with pain and restrictions in diet. Poorer HRQoL was found to be associated 
with higher HbA1c, which indicates poorer glycemic control. The chronicity of DM 
and use of insulin may have negative impact on patients’ HRQoL. 
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OBJECTIVES: To examine the association between patterns of cardiovascular medica-
tion use and health-related quality of life (HRQoL) in elderly Australian women with 
diabetes. METHODS: A cross-sectional study was conducted using older cohort com-
pleting Survey 4 in the Australian Longitudinal Study on Women’s Health (ALSWH) 
who self-reported to have been diagnosed with diabetes and/or use medications indica-
tive of diabetes. Use of cardiovascular medications was identiﬁ ed from self-reported 
medications belonging to the Anatomical Therapeutic Chemical (ATC) code B01AC, 
C03, C07, C08, C09, C02 and C10. Usage patterns were classiﬁ ed as no use, using any 
hypertensives, lipid lowering agents or antiplatelet drugs, using any two classes, and 
using all the three classes. The SF-36 was used to measure HRQoL, focusing on the 
